Welcome to our dedicated page for Utah Med Prods news (Ticker: UTMD), a resource for investors and traders seeking the latest updates and insights on Utah Med Prods stock.
Utah Medical Products, Inc. (UTMD) is a Nasdaq-listed medical device manufacturer focused on specialty instruments for hospital and clinical use, with particular emphasis on health care for women and their babies. This news page aggregates company press releases and third-party coverage so readers can follow how business developments, financial performance and governance decisions evolve over time.
Recent news items highlight several recurring themes. The company regularly reports quarterly and annual financial results, detailing changes in revenues, gross profit, operating income and earnings per share, along with commentary on factors such as OEM demand, distributor ordering patterns, foreign currency effects and litigation expenses. These earnings-related updates give investors insight into trends in domestic and outside-the-U.S. sales, including sales to OEM customers like PendoTECH and to distributors for blood pressure monitoring kits and Filshie Clip System devices.
Utah Medical Products also issues announcements about its capital allocation, including quarterly cash dividends and incremental dividend increases approved by the Board of Directors. Additional governance news has included the appointment of new directors with backgrounds in securities regulation, legal counsel and global direct end-user sales, along with information on board committee assignments and equity awards.
For followers of the surgical and medical instrument manufacturing sector, UTMD’s news provides a detailed view of how a specialty device company manages international operations, product mix, tariffs, and exchange-rate exposure. Investors, analysts and industry observers can use this page to review historical announcements, monitor ongoing financial performance and track board and dividend decisions that shape the company’s long-term profile.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Utah Medical Products reported its 1Q 2023 financial results, showing a 1.6% increase in revenues to $12,520k compared to the same period in 2022. The gross profit rose by 4.1% to $7,843k. However, operating income fell 1.9% to $4,439k, indicating rising litigation expenses. Net income increased 19.2%, reaching $4,214k, with earnings per share up by 20.2% at $1.159. The gross profit margin improved to 62.6% from 61.1%. International sales surged 22.9%, while domestic sales dropped 10%. As of March 31, 2023, cash and investments totaled $80.9 million, up from $75.1 million at year-end 2022.
Utah Medical Products, Inc. (NASDAQ:UTMD) has announced a quarterly cash dividend of $0.295 per share, payable on April 4, 2023, to shareholders recorded by close of business on March 17, 2023. This marks a 1.7% increase compared to the same period last year. The company specializes in medical devices for women and babies, with products recognized globally for optimal patient outcomes. For more details on Utah Medical Products, Inc., visit www.utahmed.com.
Utah Medical Products reported a strong financial performance for 2022, with revenues increasing by 7% year-over-year, and net income rising by 11%. Despite a stronger USD impacting foreign currency sales, constant currency sales showed a 10% growth. Key metrics revealed a 3% increase in gross profit and earnings per share up by 12%. Operating income faced a slight decline of 1% due to higher legal costs. The company finished the year with $75.1 million in cash and investments, marking a 23% increase from 2021. Overall, UTMD has strengthened its balance sheet while dealing with inflationary pressures and supply chain challenges.
Utah Medical Products, Inc. (UTMD) announced a quarterly cash dividend of $0.295 per share, payable on January 4, 2023, to shareholders of record by December 16, 2022. This represents a 1.7% increase from the prior dividend. The company specializes in developing and marketing medical devices focused on women's health and neonatal care, with products recognized globally for optimal patient outcomes.
Utah Medical Products (Nasdaq: UTMD) reported a mixed financial performance for Q3 2022, with revenues rising 3% year-over-year, while gross profit and operating income saw modest increases of 1%. Net income rose by 2%, reflecting ongoing challenges like supply chain disruptions and litigation costs, as well as the impact of a stronger USD on foreign sales. Despite these hurdles, management highlighted better-than-expected results and maintained a solid cash position of $69.5 million, alongside a commitment to stock repurchases and dividends, indicating continued shareholder value focus.
Utah Medical Products (NASDAQ:UTMD) declares a quarterly cash dividend of $0.29 per share, payable on October 5, 2022, to shareholders on record by September 16, 2022. This dividend reflects a 1.8% increase compared to the same quarter last year. Utah Medical Products specializes in developing and manufacturing medical devices for women and infants, recognized globally for quality and performance.